tsh biopharmoration Ltd Total Liabilities
tsh biopharmoration Ltd total liabilities. Based on the latest financial reports, tsh biopharmoration Ltd (8432) has total liabilities worth NT$273.54 Million TWD (≈ $8.62 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of tsh biopharmoration Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of tsh biopharmoration Ltd (2017–2024)
Total liabilities of tsh biopharmoration Ltd from 2017 to 2024. This chart illustrates how tsh biopharmoration Ltd's total liabilities have evolved over time, based on quarterly financial data.
tsh biopharmoration Ltd Competitors by Total Liabilities
The table below lists competitors of tsh biopharmoration Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
5E Advanced Materials Inc
AU:5EA
|
Australia | AU$5.10 Million |
|
I&C Technology Co. Ltd
KQ:052860
|
Korea | ₩16.81 Billion |
|
Codes Combine Co. Ltd
KQ:047770
|
Korea | ₩23.36 Billion |
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
India | Rs1.37 Billion |
|
Big River Industries Ltd
AU:BRI
|
Australia | AU$145.90 Million |
|
Eyenovia Inc
NASDAQ:EYEN
|
USA | $15.70 Million |
|
Century Land Joint Stock Company
VN:CRE
|
Vietnam | ₫1.43 Trillion |
|
Northern Technologies
NASDAQ:NTIC
|
USA | $27.35 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down tsh biopharmoration Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 8432 total asset value.
Liquidity & Leverage Metrics
tsh biopharmoration Ltd Total Liabilities Ratios Explained
tsh biopharmoration Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how tsh biopharmoration Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for tsh biopharmoration Ltd (2017–2024)
The table below shows the annual total liabilities of tsh biopharmoration Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$219.22 Million ≈ $6.91 Million |
+64.06% |
| 2023-12-31 | NT$133.63 Million ≈ $4.21 Million |
-39.93% |
| 2022-12-31 | NT$222.46 Million ≈ $7.01 Million |
+159.27% |
| 2021-12-31 | NT$85.80 Million ≈ $2.70 Million |
-16.73% |
| 2020-12-31 | NT$103.04 Million ≈ $3.25 Million |
-25.76% |
| 2019-12-31 | NT$138.79 Million ≈ $4.37 Million |
+39.57% |
| 2018-12-31 | NT$99.44 Million ≈ $3.13 Million |
-26.39% |
| 2017-12-31 | NT$135.08 Million ≈ $4.26 Million |
-- |
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more